Varegacestat’s pivotal study reads out imminently.
ApexOnco Front Page
Recent articles
The pivotal Harmoni-GI3 study has started enrolling patients.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Genmab acquires the Dutch biotech for $8bn.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
